Deciphering the melanoma interactome.
Late-stage malignant melanoma continues to pose a significant therapeutic challenge, despite numerous recent advances in our understanding of the molecular and genetic pathways leading to tumor development and progression. Dr Scott McNutt was among the first researchers to employ the cutting edge technology, electron microscopy, to the study of cutaneous neoplasms. This work provided the foundation for more recent studies using molecular pathology to examine disease in the context of aberrant interactions between cellular signaling pathways in the so-called 'interactome'. Understanding the functional interrelationships of aberrant signaling networks in melanoma may lead to the development of novel therapies for advanced disease. This mini review will focus on few of the proteins that likely significantly contribute to the melanoma disease interactome.
Reed
Jon A
JA
Section of Dermatopathology, Department of Pathology, Baylor College of Medicine, Houston, TX 77030, USA. jreed@bcm.edu
D006801:Humans; D008544:Melanocytes / Q000378:metabolism* / Q000473:pathology; D008545:Melanoma / Q000235:genetics* / Q000378:metabolism / Q000503:physiopathology; D015398:Signal Transduction / Q000502:physiology*; D012878:Skin Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000503:physiopathology